Early evaluation of liposomal daunorubicin (DaunoXome(R), Nexstar) in the treatment of relapsed and refractory lymphoma

被引：33

作者：

Richardson, DS ^{[1
]}

Kelsey, SM ^{[1
]}

Johnson, SA ^{[1
]}

Tighe, M ^{[1
]}

Cavenagh, JD ^{[1
]}

Newland, AC ^{[1
]}

机构：

[1] TAUNTON & SOMERSET HOSP,DEPT HAEMATOL,TAUNTON,MA

来源：

INVESTIGATIONAL NEW DRUGS | 1997年 / 15卷 / 03期

关键词：

daunorubicin; liposomes; lymphoma;

D O I：

10.1023/A:1005879219554

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We have treated 19 patients with relapsed or refractory lymphoma with liposomally encapsulated daunorubicin (DaunoXome) at two dose schedules; 40 mg/m(2) repeated every 14 days and 120 mg/m(2) repeated every 21 days. Non-haematological toxicity was mild, in particular, no patient treated with the higher dose schedule showed clinical deterioration in cardiac function. At the lower dose (10 patients) no objective responses were seen but at the higher dose (9 patients) one complete response and two partial responses were achieved. Liposomal daunorubicin at 120 mg/m(2) appears to have some activity against refractory lymphoma and we suggest that further studies with this agent are required.

引用

页码：247 / 253

页数：7

共 24 条

[1]

Carlson R W, 1992, Oncology (Williston Park), V6, P95

[2] IMPROVED CELLULAR ACCUMULATION IS CHARACTERISTIC OF ANTHRACYCLINES WHICH RETAIN HIGH-ACTIVITY IN MULTIDRUG RESISTANT CELL-LINES, ALONE OR IN COMBINATION WITH VERAPAMIL OR CYCLOSPORINE-A [J].